U.S. Office REITs Stock News

Earlier this year, COMPASS Pathways reported that its lead therapy, COMP360, achieved statistically significant reductions in depressive symptoms in a Phase 3 program and advanced a rolling FDA New Drug Application, materially lowering regulatory uncertainty around its first potential product. This progress marks a shift from pure clinical research toward building a commercial-scale mental health platform, which could make COMPASS Pathways more interesting to larger pharmaceutical companies...

Earlier this month, Watts Water Technologies reported Q1 results that surpassed analyst expectations on revenue growth and profitability, aided by firm pricing, productivity gains under its One Watts system, and resilient demand across key end markets. The company’s emphasis on innovation, higher-growth opportunities, and recent acquisitions appears to be broadening its revenue base and strengthening its positioning in attractive water infrastructure segments. Next, we examine how strong Q1...

Recent commentary on Yum China Holdings (YUMC) points to ongoing pressure from weak same-store sales, limited pricing flexibility, and expectations for soft demand ahead. These factors appear to be shaping how investors view the stock. See our latest analysis for Yum China Holdings. The recent concerns around weak same-store sales and pricing power seem to be reflected in Yum China Holdings' share price, which is around $44.63, with the 90 day share price return down 17.35%, while the 1 year...

Earlier in June 2026, Avista Corporation signed a non-binding memorandum of understanding with a Washington-based developer for a potential large-load electric service starting at 125 megawatts in 2029, with a possible path to 500 megawatts by 2032, subject to regulatory approvals and definitive agreements. Shortly afterward, Avista paused processing new large data center energy requests, highlighting how community concerns and regulatory coordination can meaningfully shape the pace and...

Mortgage rate move puts focus on Federal Home Loan Mortgage stock Freddie Mac’s latest survey showed the average 30-year fixed mortgage rate at 6.52%, even as stronger employment trends helped existing home sales reach a five-month high and signaled renewed buyer confidence. That mix of higher borrowing costs and improving demand is front and center for investors watching Federal Home Loan Mortgage (FMCC), a core player in the US secondary mortgage market through its single-family and...

Brixmor Property Group (BRX) is back on investors’ radar after recent trading activity, following a consistent stock move over the past month and prompting closer attention to how its open air shopping center portfolio is being valued. See our latest analysis for Brixmor Property Group. At a share price of $32.58, Brixmor’s recent momentum is clear, with an 11.42% 30 day share price return and a 25.50% year to date share price return supporting a 33.40% 1 year total shareholder return. This...

Structure Therapeutics announced that Phase 2b ACCESS trial results for its oral GLP-1 receptor agonist aleniglipron in people with overweight or obesity were published in Nature Medicine and presented at the American Diabetes Association’s 86th Scientific Sessions, showing statistically significant efficacy across three maintenance doses and a safety profile consistent with the GLP-1 class. The interim open-label extension data, indicating durable weight loss beyond 36 weeks and improved...

Dover (DOV) is attracting fresh attention after reporting Q1 revenue above estimates and unveiling Markem-Imaje’s CoLOS Software Version 7, which introduces added automation and cybersecurity features for industrial coding and traceability. See our latest analysis for Dover. After the Q1 beat and the CoLOS Version 7 launch, Dover’s share price has gained 11.1% year to date and its 1-year total shareholder return of 22.23% points to steady, rather than runaway, momentum. If you are looking...

Progyny (PGNY) is back in focus after shareholders approved governance changes that remove a default supermajority voting requirement for certain deals, alongside a new $200 million share repurchase plan funded from existing cash. See our latest analysis for Progyny. The governance changes and the new buyback come as momentum in Progyny’s stock has picked up, with a 30-day share price return of 14.54% and a 90-day share price return of 47.53%. The 1-year total shareholder return of 26.45%...

Class action lawsuit raises fresh questions for Regencell Bioscience Holdings Pomerantz LLP has launched a class action lawsuit against Regencell Bioscience Holdings (NasdaqCM:RGC) and certain officers, alleging securities law violations tied to a gap between the company’s public statements and its underlying business profile. See our latest analysis for Regencell Bioscience Holdings. The class action comes after a period of sharp volatility for Regencell, with the stock falling 34.11% on a...

In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.

In the last week, the United States market has stayed flat, yet it has seen a significant rise of 24% over the past year with earnings forecasted to grow by 19% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often suggest confidence in a company's future prospects and alignment of interests between management and shareholders.

Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyond well-known stocks, penny stocks — often representing smaller or newer companies — can present intriguing opportunities. Despite being a somewhat outdated term, penny stocks remain a relevant investment area for those seeking potential growth and financial resilience in lesser-known companies.

In the last week, the United States market has stayed flat, but it is up 24% over the past year with earnings forecast to grow by 19% annually. In such a dynamic environment, reliable dividend stocks like Automatic Data Processing and others can offer stability and consistent income for investors seeking dependable returns.

SpaceX’s record US$85.7b IPO and the early jump in its share price have pushed capital markets’ attention firmly toward the plumbing behind large scale space and AI infrastructure. When a single listing highlights how much money is chasing orbital AI data centers and related hardware, it can reshape how investors think about the suppliers, software platforms, and backbone systems that might benefit or face tougher expectations. This article highlights 3 stocks from an AI Infrastructure...

In recent months, FirstCash Holdings has come under scrutiny as some analysts argue the stock trades well above its estimated intrinsic value, while insiders have sold US$6,200,000 of shares over a three‑month period. This combination of perceived overvaluation and insider selling has sharpened investor focus on how closely FirstCash’s market price aligns with its underlying fundamentals. Next, we’ll examine how concerns about FirstCash’s valuation premium shape the company’s broader...

In June 2026, Robert Half Inc. filed a US$110.84 million shelf registration for 3,508,625 common shares tied to an ESOP-related offering. At the same time, easing geopolitical tensions and new survey data showing more professionals preparing job moves could influence demand for Robert Half’s staffing and consulting services. We’ll now examine how improving geopolitical conditions and stronger job-seeker activity feed into Robert Half’s existing investment narrative and outlook. AI is about...

In April 2026, Indivior Pharmaceuticals raised its full-year net revenue and adjusted EBITDA guidance after strong first-quarter results driven by expanded uptake of its long-acting opioid use disorder treatment SUBLOCADE, and announced a US$175,000,000 accelerated share repurchase to be completed by the end of June 2026. This combination of stronger operating performance and a shift in capital allocation toward share buybacks highlights management’s increasing focus on profitability and...

In recent days, Equifax’s latest quarterly update and analyst commentary have highlighted concerns about its exposure to interest rate–sensitive mortgage revenue and evolving credit-reporting regulations, even as the company reaffirmed full-year guidance and reported earnings above expectations earlier in 2026. At the same time, Equifax Canada’s move to offer a free Credit Lock service in Ontario under new provincial legislation underscores how regulatory shifts can simultaneously pressure...

SharonAI Holdings (SHAZ) has become a focus for investors after announcing a six-year AI compute collaboration with NVIDIA to deploy 72MW of data center capacity in Australia, targeting AI startups, enterprises, and researchers. See our latest analysis for SharonAI Holdings. The multi year NVIDIA collaboration comes on the heels of a recent shelf registration and a sharp pullback in AI infrastructure stocks. However, SharonAI’s 90 day share price return of 157.2% and year to date share price...

Oruka Therapeutics (NasdaqGM:ORKA) has amended its IL-23 License Agreement with Paragon Therapeutics. The revised agreement broadens therapeutic, prophylactic, palliative, and diagnostic uses tied to Oruka’s IL-23 pipeline. The amendment also changes certain restrictions related to clinical trials and future licensing terms. For Oruka Therapeutics, a company focused on IL-23 directed therapies, this move widens the scope of how its existing science can be used across disease treatment,...

Why Royal Gold’s valuation signal matters now Royal Gold (RGLD) has come into focus after a strong 91/100 GF Score and indications of modest undervaluation relative to intrinsic value models like DCF and GF Value, despite recent insider selling. See our latest analysis for Royal Gold. Recent trading has been choppy, with the share price down about 9% over 30 days and 19% over 90 days. However, the 1 year total shareholder return of 16.5% and 5 year total shareholder return of 99.7% point to...

In the most recent quarter, American Superconductor reported record results, with revenue rising 29.6% year on year and surpassing analyst expectations, highlighting what management called exceptional execution across both the quarter and full fiscal year. Despite these strong operational and financial results, the reaction among market participants has been mixed, raising questions about how sustainable current demand patterns and profitability levels may be for the business. We’ll now...

Virgin Galactic Holdings (SPCE) is back in focus after resuming glide flights, reaffirming late 2026 test and commercial timelines for its Delta class spacecraft, and executing a debt for equity swap to ease near term obligations. See our latest analysis for Virgin Galactic Holdings. That backdrop of resumed test activity and capital structure moves sits alongside sharp share price swings. The 1 day share price return fell 31.8% but the 3 month share price return was 47.6%. The 1 year total...